Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG). Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [30]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“(R)-2HG competitively inhibited BCAT1, which is a cytosolic enzyme, with respect to 2OG over a physiologically-relevant range of 2OG concentrations”
From Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma (2018) · cites this paper as Koivunen et al., 2012
Experimental — accuracy not yet measuredIn the citing paper
“Though it is found at low levels in normal cells, D-2HG can accumulate to millimolar levels in cancer cells expressing mutant IDH. At these high concentrations, D-2HG can inhibit αKG-dependent dioxygenases, including enzymes involved in histone and DNA demethylation (Chowdhury et al., 2011; Janke et al., 2017; Koivunen et al., 2012; Xu et al., 2011).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Koivunen et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Self-citationCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 1×
“Consistent with recent reports, we found that both ( R )-2HG and ( S )-2HG inhibit a number of 2-OG-dependent enzymes in vitro”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“Although HIF is typically viewed as an oncoprotein it can behave as a tumour suppressor in embryonic stem cell”
BackgroundHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 1×
“Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradatio”
BackgroundIto, S., D’Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,373 · cited 1×
“Human EGLN1, 2 and 3, collagen P4H-I and FIH, and murine Tet1 and Tet2 were produced in insect cells and purified as described earlie”
MethodAbsolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli
Bennett, B. D., Kimball, E. H., Gao, M., Osterhout, R., Van Dien, S. J., & Rabinowitz, J. D. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.186 · Cited by 1,830 · cited 1×
“Studies in model organisms suggest that many metabolic enzymes are saturated in vivo with a mixture of substrate and competitive inhibitors and thus are sensitive to changes in substrate concentrations that are far above their nominal K m value”
BackgroundGlioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 1×
“Nor are our data incompatible with the finding that HIF-1a protein levels are increased in IDH mutant tumours relative to normal brai”
ResultThe oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Cited by
Items 101–200 of 752
Molecular neuro-oncology in clinical practice: a new horizon
Weller, M., Pfister, S. M., Wick, W., Hegi, M. E., Reifenberger, G., & Stupp, R. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70168-2 · Cited by 189
“2 and 3) which in turn leads to diminished HIF levels and enhances proliferation as well as soft agar growth of human astrocytes.(6) These insights provided evidence that gliomas with IDH mutations have a distinct pathogenetic origin.”
BackgroundMolecular and cellular heterogeneity: the hallmark of glioblastoma
Aum, D. J., Kim, D. H., Beaumont, T. L., Leuthardt, E. C., Dunn, G. P., & Kim, A. H. (2014) · Neurosurgical Focus · doi:10.3171/2014.9.focus14521 · Cited by 191
Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
Kats, L. M., Reschke, M., Taulli, R., Pozdnyakova, O., Burgess, K., Bhargava, P., Straley, K., Karnik, R., Meissner, A., Small, D., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2013.12.016 · Cited by 187
“, 2011) and others reporting inactivation (Koivunen et al., 2012; Losman et al., 2013), albeit in different systems.”
BackgroundDelgado‐Martín, B., & Medina, M. Á. (2020) · Advanced Science · doi:10.1002/advs.201902971 · Cited by 191
Matias, D., Balça-Silva, J., da Graça, G. C., Wanjiru, C. M., Macharia, L. W., Nascimento, C. P., Roque, N. R., Coelho-Aguiar, J. M., Pereira, C. M., Dos Santos, M. F., et al. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00235 · Cited by 180
The CpG Island Methylator Phenotype: What's in a Name?
Hughes, L. A. E., Melotte, V., de Schrijver, J., de Maat, M., Smit, V. T. H. B. M., Bovée, J. V. M. G., French, P. J., van den Brandt, P. A., Schouten, L. J., de Meyer, T., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4306 · Cited by 186
“Finally, a mechanism altering hypoxia-inducible factor (HIF) expression is involved (81).”
Backgroundde la Fuente, M. I., Young, R. J., Rubel, J., Rosenblum, M., Tisnado, J., Briggs, S., Arevalo-Perez, J., Cross, J. R., Campos, C., Straley, K., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov307 · Cited by 193
Redox Potential of Antioxidants in Cancer Progression and Prevention
George, S., & Abrahamse, H. (2020) · Antioxidants · doi:10.3390/antiox9111156 · Cited by 178
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer
Kaelin, W. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162480 · Cited by 161
“In parabiosis experiments we confirmed that the Surprisingly, we found that 2-HG could stimulate EglN activity, which would explain the low HIF levels observed in IDH mutant gliomas (89).”
BackgroundMolenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., van Noorden, C. J. F., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 182
Chen, C., Liu, Y., Lu, C., Cross, J. R., Morris, J. P., Shroff, A. S., Ward, P. S., Bradner, J. E., Thompson, C., & Lowe, S. W. (2013) · Genes & Development · doi:10.1101/gad.226613.113 · Cited by 182
“In the hematopoietic system and other cell types, these changes are associated with a differentiation block (Koivunen et al. 2012; Lu et al. 2012; Sasaki et al. 2012; Turcan et al. 2012).”
BackgroundMetabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells
Caino, M. C., Chae, Y. C., Vaira, V., Ferrero, S., Nosotti, M., Martin, N. M., Weeraratna, A., O’Connell, M., Jernigan, D., Fatatis, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67841 · Cited by 183
“Although energetically unfavorable (3), cancer metabolism contributes to biomass expansion (4), oncogenic signaling (5), generation of biochemical defects that further the malignant phenotype (6, 7), and transformation-associated epigenetic changes (8, 9).”
Oncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 178
“Whilst the role of D-2HG in PHD inhibition and HIF stabilisation is still controversial [75], this metabolite was shown to inhibit both TETs and KDMs [76,77].”
BackgroundLong-term reprogramming of the innate immune system
Dominguez-Andres, J., & Netea, M. G. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-104r · Cited by 170
Cassim, S., Vučetić, M., Ždralević, M., & Pouyssegur, J. (2020) · Cancers · doi:10.3390/cancers12051119 · Cited by 175
Seim, G. L., Britt, E. C., John, S. V., Yeo, F. J., Johnson, A. R., Eisenstein, R. S., Pagliarini, D. J., & Fan, J. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0083-2 · Cited by 178
Tommasini-Ghelfi, S., Murnan, K., Kouri, F. M., Mahajan, A. S., May, J. L., & Stegh, A. H. (2019) · Science Advances · doi:10.1126/sciadv.aaw4543 · Cited by 168
Metabolic changes in cancer: beyond the Warburg effect
Wu, W., & Zhao, S. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms104 · Cited by 173
A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma
Lorenzo, F. R., Yang, C., Ng Tang Fui, M., Vankayalapati, H., Zhuang, Z., Huynh, T., Grossmann, M., Pacak, K., & Prchal, J. T. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0967-z · Cited by 171
“In many instances, such as VHL syndrome, upregulated HIFs are tumor promoter genes, but in some contexts, HIFs can also have a role as tumor suppressors [20].”
HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells
Lee, S.-H., Golinska, M., & Griffiths, J. R. (2021) · Cells · doi:10.3390/cells10092371 · Cited by 169
Self-citationTCA Cycle Defects and Cancer: When Metabolism Tunes Redox State
Cardaci, S., & Ciriolo, M. R. (2012) · International Journal of Cell Biology · doi:10.1155/2012/161837 · Cited by 161
“Moreover, they pointed out that HIF1α downregulation enhances the proliferation of human astrocytes and promotes their transformation, providing a justification for exploring PHDs inhibition as a potential treatment strategy for tumors harboring IDH1/2 mutations [40].”
BackgroundWhat do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1106-9 · Cited by 166
“Furthermore, the two enantiomers of 2-HG differ in their potency, with L-2-HG generally being a better inhibitor of a-KG-dependent enzymes than D-2-HG [30] [87] [184].”
InfluentialHIF1A Reduces Acute Lung Injury by Optimizing Carbohydrate Metabolism in the Alveolar Epithelium
Eckle, T., Brodsky, K., Bonney, M., Packard, T., Han, J., Borchers, C. H., Mariani, T. J., Kominsky, D. J., Mittelbronn, M., & Eltzschig, H. K. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001665 · Cited by 165
“In fact, previous studies had indicated that normoxic stabilization of HIF in cancer involves inhibition or mutation of the metabolic enzyme SDH [46,48].”
BackgroundMetabolic coordination of cell fate by α-ketoglutarate-dependent dioxygenases
Baksh, S. C., & Finley, L. W. S. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.09.010 · Cited by 165
“Mechanistically, changes in TCA cycle metabolites are postulated to affect cell fate by regulating activity of α-ketoglutarate-dependent dioxygenases [12,13].”
BackgroundThe Roles of 2-Hydroxyglutarate
Du, X., & Hu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651317 · Cited by 177
“By which enantiomer accumulates in the body fluids, it can be classified into D-2HGA, L-2HGA, and “combined D,L-2hydroxyglutaric aciduria” (D,L-2HGA) (Kranendijk et al., 2012).”
BackgroundInfluentialMetabolic consequences of oncogenic IDH mutations
Parker, S. J., & Metallo, C. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.003 · Cited by 158
“Several studies have subsequently indicated that both L-2HG and D-2HG can act as competitive inhibitors of αKG-dependent dioxygenases, including the EglN family of prolyl hydroxylases (PHDs), the TET family of DNA demethylases, and the JmjC family of histone demethylases (Chowdhury et al., 2011; Xu et al., 2011; Koivu…”
BackgroundResultInfluentialOncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 173
“It was initially reported that IDH1 mutations led to HIF-1 stabilization,37 but Koivunen et al. then showed that (R)2-HG efficiently inhibits a number of 2-OG-dependent dioxygenases, but does not inhibit PHDs.38 Instead, (R)2-HG was reported to be capable of promoting the activity of PHD1 and 2, and to a lesser extent…”
BackgroundWu, M.-J., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.-Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1077 · Cited by 155
Burr, S. P., Costa, A. S. H., Grice, G. L., Timms, R. T., Lobb, I. T., Freisinger, P., Dodd, R. B., Dougan, G., Lehner, P. J., Frezza, C., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.015 · Cited by 164
“Whether D-2-HG can activate HIF1a (Koivunen et al., 2012) is unclear from our studies.”
BackgroundInfluentialLi, S., Chou, A. P., Chen, W., Chen, R., Deng, Y., Phillips, H. S., Selfridge, J., Zurayk, M., Lou, J. J., Everson, R. G., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos261 · Cited by 155
Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017) · Cancer · doi:10.1002/cncr.31039 · Cited by 168
“to decreased hypoxia-inducible factor (HIF) levels and increased tumor proliferation and growth.(25) Finally, ele-”
BackgroundMetabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 157
“IDH1 mutant glioma cells reduce the production of α-KG and increase HIF-1α and its target genes (GLUT1, VEGF, and PDK1) to stimulate tumor growth and angiogenesis [134], whereas IDH1 mutants have also been shown to stimulate EglN prolyl 4-hydroxylase, which destabilizes HIF-1α and diminishes the expression of its targ…”
BackgroundZhang, J., Yao, M., Xia, S., Zeng, F., & Liu, Q. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00682-7 · Cited by 126
Radioprotection of IDH1 -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Molenaar, R. J., Botman, D., Smits, M. A., Hira, V. V., van Lith, S. A., Stap, J., Henneman, P., Khurshed, M., Lenting, K., Mul, A. N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3603 · Cited by 148
“D-2HG and L-2HG are competitive inhibitors of aKG-dependent enzymes (7, 8, 41).”
BackgroundOncometabolites: tailoring our genes
Nowicki, S., & Gottlieb, E. (2015) · The FEBS Journal · doi:10.1111/febs.13295 · Cited by 143
Tiwari, A., Tashiro, K., Dixit, A., Soni, A., Vogel, K., Hall, B., Shafqat, I., Slaughter, J., Param, N., Le, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.07.046 · Cited by 142
Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
Yu, D., Liu, Y., Zhou, Y., Ruiz‐Rodado, V., Larion, M., Xu, G., & Yang, C. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913633117 · Cited by 148
Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes
Wong, B. W., Kuchnio, A., Brüning, U., & Carmeliet, P. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.10.004 · Cited by 159
Acidic pH Is a Metabolic Switch for 2-Hydroxyglutarate Generation and Signaling
Nadtochiy, S. M., Schafer, X., Fu, D., Nehrke, K., Munger, J., & Brookes, P. S. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.738799 · Cited by 143
“However, due to saturation of the HIF signal, low exposure blots were used for the hypoxia condition.”
BackgroundInfluentialOncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling
Gagné, L. M., Boulay, K., Topisirović, I., Huot, M., & Mallette, F. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.002 · Cited by 151
Andronesi, O. C., Arrillaga‐Romany, I., Ly, I., Bogner, W., Ratai, E., Reitz, K., Iafrate, A. J., Dietrich, J., Gerstner, E. R., Chi, A. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03905-6 · Cited by 149
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
Shi, D. D., Savani, M. R., Levitt, M. M., Wang, A. C., Endress, J. E., Bird, C. E., Buehler, J., Stopka, S. A., Regan, M. S., Lin, Y., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.011 · Cited by 153
“Stable NHA cell lines expressing either EV or IDH1-R132H were generated using pBabe-hygro (model #1) or pLenti-EF1α-IRES-hygro (model #2) plasmid backbone and cDNA cloning strategies as previously described (Koivunen et al., 2012; McBrayer et al., 2018).”
BackgroundMethodSelf-citationRole of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
Chan, S. M., & Majeti, R. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1407-8 · Cited by 131
“Surprisingly, D-2-HG was found to be an agonist of EglN activity leading to diminished levels of HIF-1a in some cellular contexts [57].”
Deng, G., Shen, J., Yin, M., McManus, J., Mathieu, M., Gee, P., He, T., Shi, C., Bedel, O., McLean, L. R., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608497 · Cited by 135
“2HG has also been proposed to promote oncogenic transformation by activating EGLN, an -ketoglutarate-dependent prolyl hydroxylase involved in the hypoxia-inducible factor signaling pathway (16).”
BackgroundTargeting mitochondria in cancer: current concepts and immunotherapy approaches
Pustylnikov, S., Costabile, F., Beghi, S., & Facciabene, A. (2018) · Translational research · doi:10.1016/j.trsl.2018.07.013 · Cited by 144
Hypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics
Burroughs, S. K., Kaluz, S., Wang, D., Wang, K., Van Meir, E. G., & Wang, B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.17 · Cited by 140
Metabolic Reprogramming in Brain Tumors
Venneti, S., & Thompson, C. B. (2017) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044329 · Cited by 153
Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells
Chen, S., & Sang, N. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25283 · Cited by 145
“More recent reports demonstrate that mutations in IDH1 or IDH2 result in the formation of abnormal metabolite (R)-2-hydroxylglutarate, which stimulates PHD activity, thus decreasing HIF-1a protein levels in gliomas [Koivunen et al., 2012].”
BackgroundBorger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., Christiani, D. C., Liebman, H. M., Yang, H., Kim, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2649 · Cited by 138
“Another target of 2HG is the EglN prolyl 4-hydroxylases thatpromoteproteasomaldegradationof the hypoxia-inducible factor transcription factor (11, 24, 29).”
Nota, B., Struys, E. A., Pop, A., Jansen, E. E., Fernandez Ojeda, M. R., Kanhai, W. A., Kranendijk, M., van Dooren, S. J. M., Bevova, M. R., Sistermans, E. A., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.03.009 · Cited by 138
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma
Zhang, C., Moore, L. M., Li, X., Yung, W. K. A., & Zhang, W. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not087 · Cited by 150
“In structure, 2-HG is similar to a-ketoglutarate and competitively inhibits the enzymatic activity of dioxygenases.(60) Thus, inhibition of dioxygenases by 2-HG is believed to be one mechanism through which IDH1/2 mutations contribute to the pathogenesis of gliomas (Fig.”
BackgroundPrecancer Atlas to Drive Precision Prevention Trials
Spira, A., Yurgelun, M. B., Alexandrov, L., Rao, A., Bejar, R., Polyak, K., Giannakis, M., Shilatifard, A., Finn, O. J., Dhodapkar, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2346 · Cited by 129
Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
Al‐Khallaf, H. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0165-3 · Cited by 152
Control of endothelial quiescence by FOXO-regulated metabolites
Andrade, J., Shi, C., Costa, A. S. H., Choi, J., Kim, J., Doddaballapur, A., Sugino, T., Ong, Y. T., Castro, M., Zimmermann, B., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00637-6 · Cited by 138
The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity
Vatrinet, R., Leone, G., Luise, M. D., Girolimetti, G., Vidone, M., Gasparre, G., & Porcelli, A. M. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0165-0 · Cited by 141
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer
Karlstaedt, A., Moslehi, J. J., & de Boer, R. A. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00698-6 · Cited by 140
Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Jin, G., Reitman, Z. J., Duncan, C. G., Spasojevic, I., Gooden, D. M., Rasheed, B. A., Yang, R., Lopez, G. Y., He, Y., McLendon, R. E., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2852 · Cited by 125
“Knock-in of an IDH1 allele to produce heterozygous IDH1 (13) resulted in more than 100-fold higher D-2HG than the parental IDH1 HCT116 cells.”
Self-citation2-Hydroxyglutarate in Cancer Cells
Ježek, P. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130
Zheng, X., Zhai, B., Koivunen, P., Shin, S. J., Lu, G., Liu, J., Geisen, C., Chakraborty, A. A., Moslehi, J. J., Smalley, D. M., et al. (2014) · Genes & Development · doi:10.1101/gad.242131.114 · Cited by 128
“Notably, EglN2 / mice display decreased oxygen consumption and increased hypoxia tolerance associated with increased expression of pyruvate dehydrogenase 4 (PDK4), which is responsive to FOXO3a (Kwon et al. 2004; Aragones et al. 2008).”
BackgroundSelf-citationPharmacological targeting of the HIF hydroxylases – A new field in medicine development
Chan, M. C., Holt‐Martyn, J. P., Schofield, C. J., & Ratcliffe, P. J. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.01.001 · Cited by 133
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
Karsy, M. J., Guan, J., Cohen, A. L., Jensen, R. L., & Colman, H. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0722-5 · Cited by 146
Hypoxia-inducible factors in cancer stem cells and inflammation
Peng, G., & Liu, Y. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.003 · Cited by 123
“One study showed that IDH mutations increase HIF1α accumulation [25, 26]; while a later study suggested an opposite effect [32].”
Lemonnier, F., Cairns, R. A., Inoue, S., Li, W. Y., Dupuy, A., Broutin, S., Martin, N., Fataccioli, V., Pelletier, R., Wakeham, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617929114 · Cited by 121
Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
Miranda‐Gonçalves, V., Lameirinhas, A., Henrique, R., & Jerónimo, C. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00427 · Cited by 136
Böttcher, M., Renner, K., Berger, R., Mentz, K., Thomas, S., Cardenas-Conejo, Z. E., Dettmer, K., Oefner, P. J., Mackensen, A., Kreutz, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1445454 · Cited by 124
“accumulation promote prolyl hydroxylase activity that targets the HIF-1a protein stability.(44) Treating T-cells with D-2HG Figure 3.”
BackgroundQuantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation
Ohka, F., Ito, M., Ranjit, M., Senga, T., Motomura, A., Motomura, K., Saito, K., Kato, K., Kato, Y., Wakabayashi, T., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-1784-5 · Cited by 128
“Additionally, many HIF1α responsive genes are also downregulated in IDH1 mutated cells.”
BackgroundInfluentialKonopleva, M., Thall, P. F., Yi, C. A., Borthakur, G. M., Coveler, A. L., Bueso‐Ramos, C. E., Benito, J., Konoplev, S. N., Gu, Y., Ravandi, F., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.118455 · Cited by 134
“Median percentage BM blasts (range) 35 (8-98)”
Molecular classification of gliomas
Masui, K., Mischel, P. S., & Reifenberger, G. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00006-2 · Cited by 137
Xing, Z., Yang, X., She, D., Lin, Y., Zhang, Y., & Cao, D. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5171 · Cited by 134
“in decreased hypoxia-inducible-factor 1- activation and downstream inhibition of angiogenesis-related signaling.(38,40) As demonstrated by Kickingereder et al(18) that IDH-mutant and wild-type”
MethodIDH1 Mutation Induces Reprogramming of Pyruvate Metabolism
Izquierdo-Garcia, J. L., Viswanath, P., Eriksson, P., Cai, L., Radoul, M., Chaumeil, M. M., Blough, M., Luchman, H. A., Weiss, S., Cairncross, J. G., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0840 · Cited by 123
“Koivunen and colleagues (41) showed that introduction of the IDH1 mutation or addition of 2-HG to cell lines resulted in diminished HIF1a levels and reduced expression of HIF1a target genes.”
BackgroundSelf-citationProlyl 4‐hydroxylases, master regulators of the hypoxia response
Myllyharju, J. (2013) · Acta Physiologica · doi:10.1111/apha.12096 · Cited by 134
“Unexpectedly, (R)2HG was found to stimulate HIF-P4H activity thus reducing HIF levels, which was found to increase the proliferation and soft agar growth of astrocytes (Koivunen et al. 2012).”
BackgroundEffective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
Pellegatta, S., Valletta, L., Corbetta, C., Patanè, M., Zucca, I., Riccardi Sirtori, F., Bruzzone, M. G., Fogliatto, G., Isacchi, A., Pollo, B., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0180-0 · Cited by 122
“Subsequent studies had difficulties in replicating those findings [29,30].”
Grassian, A. R., Lin, F., Barrett, R., Liu, Y., Jiang, W., Korpal, M., Astley, H., Gitterman, D., Henley, T., Howes, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417832 · Cited by 121
“Reversibility of Mutant IDH Phenotypes—Recent data suggest thatmutant IDH-dependent phenotypes can take a considerable amount of time to develop; an IDH mutant mouse knock-in model has a long latency (32), and in vitro, mutant IDHoverexpressionmodels appear to require extended periods in culture before robust phenotyp…”
BackgroundEmerging Epigenetic Targets and Therapies in Cancer Medicine
Popovic, R., & Licht, J. D. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0076 · Cited by 116
Non-invasive metabolic imaging of brain tumours in the era of precision medicine
Kim, M. M., Parolia, A., Dunphy, M. P., & Venneti, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.108 · Cited by 117
Xing, F., Luan, Y., Cai, J., Wu, S., Mai, J., Gu, J., Zhang, H., Li, K., Lin, Y., Xiao, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.037 · Cited by 120
“For instance, 2-hydroxyglutarate (2-HG) has recently been shown to drive the malignant transformation of human astrocytes along with the activation of prolylhydroxylases of the EGLN family (Koivunen et al., 2012).”
BackgroundChoi, K. S., Choi, S. H., & Jeong, B. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz095 · Cited by 118
5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy
Vasanthakumar, A., & Godley, L. A. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.02.009 · Cited by 128
Desideri, E., Vegliante, R., & Ciriolo, M. R. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.023 · Cited by 124
Kaminska, B., Czapski, B., Guzik, R., Król, S. K., & Gielniewski, B. (2019) · Molecules · doi:10.3390/molecules24050968 · Cited by 120
“In addition to inducing epigenetic deregulation, (R)-2HG can regulate the activity of α-KG-dependent dioxygenases, specifically EGLN (EGL nine homolog 1) prolyl 4-hydroxylases [65], that are responsible for regulation of HIF1α, which controls angiogenesis.”
BackgroundThe Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells
Smolková, K., & Ježek, P. (2012) · International Journal of Cell Biology · doi:10.1155/2012/273947 · Cited by 106
“inhibition of EGLN prolyl 4-hydroxylases, has been reported [99].”
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
Liu, X., & Gong, Y. (2019) · Biomarker Research · doi:10.1186/s40364-019-0173-z · Cited by 119
Colvin, H., Nishida, N., Konno, M., Haraguchi, N., Takahashi, H., Nishimura, J., Hata, T., Kawamoto, K., Asai, A., Tsunekuni, K., et al. (2016) · Scientific Reports · doi:10.1038/srep36289 · Cited by 109
TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition
Morin, A., Goncalves, J., Moog, S., Castro‐Vega, L. J., Job, S., Buffet, A., Fontenille, M., Woszczyk, J., Gimenez‐Roqueplo, A., Letouzé, É., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.022 · Cited by 115
New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
Dimitrov, L., Hong, C. S., Yang, C., Zhuang, Z., & Heiss, J. D. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11047 · Cited by 117
“It has been proposed that because R-2-HG is very similar structurally to a-KG, it may act as a direct competitive inhibitor of a-KG-dependent dioxygenases such as TET2 [59, 76, 77].”
BackgroundEstablishment of patient-derived organoid models of lower-grade glioma
Abdullah, K. G., Bird, C. E., Buehler, J., Gattie, L. C., Savani, M. R., Sternisha, A. C., Xiao, Y., Levitt, M. M., Hicks, W. H., Li, W., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab273 · Cited by 113
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity
Wu, M., Kondo, H., Kammula, A. V., Shi, L., Xiao, Y., Dhiab, S., Xu, Q., Slater, C. J., Avila, O. I., Merritt, J., et al. (2024) · Science · doi:10.1126/science.adl6173 · Cited by 116
“…models included TS516 and TS603 [sexes unknown, obtained from I. Mellinghoff at the Memorial Sloan Kettering Cancer Center, New York, NY ( 63 ( 72 )]; HK211 (female), HK213 (male), HK252 (male), HK308 (female), and HK157 (female) [obtained from H. Kornblum at the University of California –…”
How metabolites modulate metabolic flux
Wegner, A., Meiser, J., Weindl, D., & Hiller, K. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.11.008 · Cited by 110
“In addition to an oxygen dependent regulation, it has been shown that the activity of PHD2 as well as other 2OG dependent dioxygenases can be regulated by the level of succinate and 2OG, as well as by fumarate and the oncometabolite 2-hydroxyglutarate (2HG) [25,26 ,27,28,29,30].”
BackgroundThe Metabolic Alterations of Cancer Cells
Sciacovelli, M., Gaude, E., Hilvo, M., & Frezza, C. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416618-9.00001-7 · Cited by 116
Genovese, G., Ergun, A., Shukla, S. A., Campos, B., Hanna, J., Ghosh, P., Quayle, S. N., Rai, K., Colla, S., Ying, H., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0111 · Cited by 105
An epigenetic gateway to brain tumor cell identity
Mack, S. C., Hubert, C. G., Miller, T. E., Taylor, M. D., & Rich, J. N. (2015) · Nature Neuroscience · doi:10.1038/nn.4190 · Cited by 109
Metabolic dysregulation in monogenic disorders and cancer — finding method in madness
Erez, A., & DeBerardinis, R. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3949 · Cited by 105
IDH inhibition in gliomas: from preclinical models to clinical trials
Rudà, R., Horbinski, C., van den Bent, M. J., Preusser, M., & Soffietti, R. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00967-7 · Cited by 113
Blockade of Glutathione Metabolism in IDH1 -Mutated Glioma
Tang, X., Fu, X., Liu, Y., Yu, D., Cai, S. J., & Yang, C. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0103 · Cited by 107
“The accumulation of 2-HG has been reported to 22 associate with glioma oncogenesis by inhibiting α-ketoglutarate dioxygenases (8-10).”
BackgroundCancer Metabolism: Fueling More than Just Growth
Lee, N., & Kim, D. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.0310 · Cited by 105
“Though D-2HG and L-2HG can exert disparate roles in prolyl hydroxylases (PDHs), respectively (Koivunen et al., 2012; Terunuma et al., 2014), both D-2HG and L-HG act as a suppressor of histone demethylases.”
BackgroundTateishi, K., Higuchi, F., Miller, J. J., Koerner, M. V. A., Lelic, N., Shankar, G. M., Tanaka, S., Fisher, D. E., Batchelor, T. T., Iafrate, A. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2263 · Cited by 103
“5 hydroxyglutarate (2HG)(18), modulation of HIF1α(19), pyruvate dehydrogenase(20), and lactate”
Molenaar, R. J., Thota, S., Nagata, Y., Patel, B., Clemente, M., Przychodzen, B., Hirsh, C., Viny, A. D., Hosano, N., Bleeker, F. E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.91 · Cited by 94
Understanding genomic alterations in cancer genomes using an integrative network approach
Wang, E. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.050 · Cited by 102
The mitochondrial side of epigenetics
Castegna, A., Iacobazzi, V., & Infantino, V. (2015) · Physiological Genomics · doi:10.1152/physiolgenomics.00096.2014 · Cited by 95
“been suggested that R-2HG selectively stimulates the activity of EglN prolyl-hydroxylases, 335 which modify the hypoxia-inducible transcription factor (HIF-1α) (56).”
BackgroundHypoxia-mediated drug resistance in breast cancers
McAleese, C. E., Choudhury, C., Butcher, N. J., & Minchin, R. F. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.045 · Cited by 106
Metadata
- Authors
- Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., Travins, J., Weiss, S., Looper, R., Ligon, K. L., Verhaak, R. G. W., Yan, H., & Kaelin Jr, W. G.
- Affiliations
- University of Oulu (FI)
- Brigham and Women's Hospital (US)
- Duke University (US)
- Agios Pharmaceuticals (United States) (US)
- University of Calgary (CA)
- University of Utah (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 484-488
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656605
- OpenAlex
- W2142898716
- Cited by
- 727
- References
- 41
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 38 · 2023: 32 · 2022: 35 · 2021: 44 · 2020: 56 · 2019: 52 · 2018: 66 · 2017: 63 · 2016: 61 · 2015: 57 · 2014: 70 · 2013: 59 · 2012: 43
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA140316)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- R-enantiomer, IDH1 mutation, IDH2 mutation, hypoxia-inducible factor, glioma, astrocyte proliferation, oncometabolites, cancer metabolism, histone demethylation, DNA hypermethylation, CpG island methylator phenotype
- MeSH terms
- Astrocytes, Cell Line, Cell Transformation, Neoplastic, Enzyme Activation, Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Nuclear Proteins, Oncogenes, Procollagen-Proline Dioxygenase, Cell Line, Tumor, Cell Proliferation, Dioxygenases, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.